ISMP QuarterWatch Reports.
This website provides quarterly reports that identify and analyze new risks related to medications and adverse drug events submitted to the Food and Drug Administration (FDA). In the third quarter of 2018, FDA received nearly 331,000 reports about adverse drug events, which represents a 16% decrease. This report focuses on problems reported on three psychoactive medications: gabapentin, pimavanserin, and pregabalin.
No hay comentarios:
Publicar un comentario